News | February 04, 2011

Repeat MRI Screening for Breast Cancer Results in Fewer False Positives

February 4, 2011 – MRI screening for breast cancer delivers consistent rates of cancer detection and fewer false-positive results over time, according to a new study in Radiology.

While MRI can be more effective than mammography at identifying suspicious areas of the breast, it is not always able to distinguish between cancerous and benign lesions. This can result in additional testing and false-positive results that may cause anxiety for patients. A screening exam is considered to be false positive when its results recommend further testing or a biopsy of a suspicious finding, but no cancer is found.

“MRI is an excellent screening tool for breast cancer, but the higher rate of false-positive results keeps some women from undergoing the exam,” said the study’s co-author Martha B. Mainiero, M.D., director of the Anne C. Pappas Center for Breast Imaging at Rhode Island Hospital and associate professor of diagnostic imaging at The Warren Alpert Medical School of Brown University in Providence, R.I. “The goal of our study was to determine if the availability of prior MR images for comparison reduces the rate of false positives associated with the initial MRI breast screening exam.”

In the study, researchers reviewed reports from 650 consecutive screening MRI breast exams performed on women between September 2007 and December 2008 at Rhode Island Hospital. The women, who ranged in age from 25 to 81 years, were referred for MRI screening because they were considered to be at high risk for breast cancer.

Of the breast MRI results reviewed, 307 were the patient’s first, or baseline, screening exams and 343 were annual or repeat screening MRI exams.

In the baseline group, MRI identified two cancers for a cancer detection rate of 0.65 percent. In the repeat screening group, the cancer detection rate was nearly twice as high. cancer was found in four patients, for a rate of 1.17 percent.

Women undergoing a baseline exam were nearly four times more likely to be recommended for a follow-up MRI exam in six months to monitor suspicious findings (31 of 307 women, or 10.1 percent) than patients who had one or more prior MRI exams for comparison (9 of 343 women or 2.6 percent). The rate of false-positive results was 13 percent (39 of 299 patients) in the baseline exam group and 5.6 percent (19 of 341 patients) in the annual exam group.

“False positives are a risk of the breast MRI procedure, but the rate decreases following the initial round of screening,” Mainiero said. “This information should provide reassurance for high-risk patients who are considering undergoing annual MRI screening exams.”

For more information: www.radiology.RSNA.org

Related Content

AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Medic Vision Wins Japanese PMDA Clearance for iQMR Image Reconstruction Solution
News | Magnetic Resonance Imaging (MRI) | July 05, 2019
Medic Vision Imaging Solutions announced that its 3-D iterative image reconstruction technology for shortening magnetic...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

Feature | Breast Imaging | July 03, 2019 | By Greg Freiherr
Productivity and its enabler — efficiency — guided the display of products at the April...